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Orthotopic liver transplantation (OLT) represents the 
standard curative treatment for human patients affected by 
an end-stage form of life-threatening liver disease involving, 
whatever the etiology (acquired or inborn) and development 
(acute or chronic), significant loss of hepatocytes and organ 
failure (1,2). The need for reliable therapeutic approaches 
alternative to OLT, in particular involving cell therapy, has 
become progressively more urgent because of the increasing 
worldwide incidence of liver diseases, particularly end-
stage chronic liver diseases (CLDs), which is unfortunately 
associated to a significant shortage in organ availability 
(1,2). In the last two decades, several laboratories have 
performed studies designed to establish cell therapy 
procedures able to provide stable and reliable sources of 
functional hepatocytes or of hepatocyte-like cells (HLCs) 
to be used for repopulation of damaged liver parenchyma. 
To this purpose intra- or extrahepatic cells have been used 
in pre-clinical studies as a potential source of functional 
HLCs to be transplanted, including primary hepatocytes, 
liver sinusoidal-endothelial cells, mesenchymal stem cells, 
endothelial progenitor cells, liver progenitor cells and even 
macrophages. However, due to several limitations [reviewed 
in (3-6)], these procedures offered sometimes positive 
results in animal models but, with few limited exceptions, 
were not always translated to successful clinical therapeutic 
approaches. 
A potentially more promising strategy, based on the 
development of the original studies of Yamanaka’s group 
on the generation of induced pluripotent stem cells (iPSC) 
from adult cells (7,8), has led, using protocols involving 
either integrative or non-integrative strategies, to successful 
reprogramming of either murine or human fibroblasts 
into HLCs (9-12). Whatever the protocol, HLCs derived 
from iPSC usually has the ability to: (I) express hepatocyte-
related markers (albumin, α1-anti-trypsin and CYP3A4); 
(II) secrete albumin; (III) express CYP3A4 activity; (IV) 
store glycogen; and (V) take up cholesterol and indocyanine 
green. Moreover, in most cases HLCs have been shown to 
have the potential to engraft murine liver and to be used 
as tools for disease modelling (9-12). Human induced, 
PSC-derived hepatocytes (hiHeps) can indeed represent 
a multi-purpose and potentially inexhaustible source 
of viable and functional HLCs. hiHeps from a healthy 
donor can be used for drug screening and toxicology, for 
allogenic therapy as well as a source of cells to be used in 
bioengineered livers. hiHeps from a patient donor can be 
used in specific disease modelling (i.e., modelling of HCV 
infection or malaria to investigate disease progression) or 
drug screening/toxicology but reprogrammed and corrected 
iPSC, than differentiated into iPSC-derived hepatocytes, 
may be in principle also used for autologous cell therapy 
(9-11). However, for any of these applications limitations 
have been described, ranging from the general problems 
still represented by the incomplete efficiency of either 
reprogramming or differentiation step to limitations related 
to the more specific application of choice, including cell 
function and viability of these iPSC-derived hepatocytes 
as well as homogeneity of the cell population obtained 
[see ref. (9)]. In addition, for allogenic or autologous 
cell therapy involving in vivo transplantation of iPSC-
derived hepatocytes one should still consider the concerns 
associated with safety issues as well as the usually low 
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engraftment potential of transplanted iPSC-derived 
hepatocytes and their functionality at both short and long 
term (9-12). Whether cell therapy approach is specifically 
concerned, iPSC-derived hepatocytes have been used in a 
number of experimental models, but best results in terms of 
engraftment and repopulation have been reported in studies 
employing a protocol of acute liver failure performed 
in rather specific mouse models (for example fumaryl-
acetoacetate hydrolase Fah−/−/Rag2−/−/IL2rγ−/− and urokinase 
(alb-uPA) severe combined immunodeficient transgenic 
mice), in which transplanted HLCs efficiently repopulated 
damaged livers because of the proliferative advantage over 
resident hepatocytes granted by the model itself (3,9-11). 
This need for a procedure offering a growth advantage/
proliferation to transplanted HLCs, already outlined also by 
previous studies employing cells obtained from non-iPSC 
sources (3-6), is still a relevant problem for translation to 
humans. 
More recently, some laboratories obtained HLCs by 
means of direct reprogramming of adult fibroblasts through 
overexpression of specific hepatocyte-related transcription 
factors in order to circumvent the induced pluripotent state 
(13-16). Murine fibroblasts have been reprogrammed to 
HLCs by either combining transduction of Hnf1α, Gata4, 
and Foxa3 with p19(Arf) inactivation (13) or through 
ectopic expression of HNF4, Foxa1, Foxa2 or Foxa3 (14). 
Similarly, reprogramming of human fibroblasts into 
HLCs was obtained by either forced ectopic expression of 
HNF1A, FOXA3 and HNF4A (15) or by combining forced 
ectopic expression of HNF1A, HNF4A and HNF6 with the 
maturation factors ATF5, PROX1, and CEBPA (16). The 
transplanted HLCs so obtained exhibited typical hepatocyte-
like characters and properties and repopulated the livers of 
either Fah(−/−) mice (13-15) or Tet-uPA/Rag2(−/−)/γc(−/−) 
mice (16),  significantly ameliorating liver functions and/or 
prolonging survival of recipients following an experimental 
acute liver failure protocol. However, most of limitations 
intrinsically related to the employment of transplanted 
HLCs for cell therapy, either for treatment of acute or, 
even more relevant, of CLDs, still remain and direct 
reprogramming until now has only been shown in culture 
settings. 
 In a recent outstanding experimental study Song and 
coworkers (17) have offered what can be really envisaged 
as a novel and very promising approach to counteract the 
progression of CLDs: the establishment of a procedure 
designed to obtain in vivo direct reprogramming of pro-
fibrogenic hepatic myofibroblasts (MFs) into HLCs in 
fibrotic murine livers (i.e., to concur to repopulate liver 
parenchyma), that also resulted in a significant attenuation 
of liver fibrosis. Two nice ideas were at the basis of this 
study. The first was of course to investigate the feasibility 
of in vivo reprogramming of adult cells into HLCs, as a 
rationale development of procedures found to be efficient 
in culture. However the most relevant idea was without any 
doubt the “choice” of pro-fibrogenic hepatic MFs as the 
cellular target for direct reprogramming in experimental 
conditions reproducing ongoing CLDs. Indeed, experimental 
and clinical literature data from the last two decades indicate 
that liver fibrogenesis is a dynamic and highly integrated 
process that, irrespective of the aetiology (viral, toxic, 
metabolic, autoimmune or genetically-related) drives the 
progression of CLDs resulting in a progressive accumulation 
of extracellular matrix components (i.e., liver fibrosis) (18-20). 
In this scenario, hepatic MFs, which mainly originate from 
a process of activation/trans-differentiation of hepatic 
stellate cells (HSCs), are widely accepted to exert a major 
pro-fibrogenic role. Persistent activation of hepatic MFs, 
unequivocally detected practically in any clinical condition 
of CLDs, irrespective of etiology, is believed to represent 
the result of a complex interaction between growth factors, 
cytokines, chemokines, reactive oxygen species (ROS) and 
other mediators (18-20). In the pro-fibrogenic environment 
these factors are released by, and interact with, any liver 
cell population, including damaged hepatocytes, activated 
inflammatory cells and MFs. This means that direct 
reprogramming of hepatic MFs does not simply originate 
HLCs contributing to repopulate damaged parenchyma and 
improve liver functions but at the same time can diminish the 
number of MFs, an event fundamental in ameliorating liver 
fibrosis (21), then realizing in a futurable and even improved 
perspective the old dream of generations of hepatologists 
that devoted efforts to find a way to specifically block and/or 
revert in vivo activated hepatic MFs. 
In their study, Song and coworkers (17) first successfully 
obtained HLCs, defined as iHep, by direct reprogramming 
murine MFs derived from activation of primary culture of 
HSCs by means of simultaneous overexpression of FOXA3, 
GATA4, HNF1A and HNF4A (i.e., by cloning cDNAs 
into a polycistronic lentiviral vector). The hepatocyte-like 
phenotype was obtained within 14 days and confirmed by 
several analyses, including the classical assays for Cyp3A 
and Cyp1A1 activity, glycogen storage, uptake of LDL and 
albumin secretion. In particular, Authors transduced cells at 
day 10 with a reporter lentiviral vector expressing dTomato 
under the transcriptional control of albumin promoter 
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and found that approx. 12% of cells expressed dTomato 
to confirm generation of HLCs. Following fluorescence-
activated cell sorting, iHep showed increased transcription 
of typical markers of primary hepatocytes in parallel with 
disappearance of critical MFs markers. Of interest, iHep 
maintained genomic integrity and, although acquiring a 
hepatocyte-like gene expression profile, remained a distinct 
cell type when compared to primary murine hepatocytes. 
Authors then established a complex lineage-tracing 
murine model suitable to detect in vivo reprogramming of 
non-parenchymal cells into iHep with the four transcription 
factors (4TS). Authors used Gt(ROSA)26Sortm4(ACTB-
tdTomato, -EGFP) mice (mT/mG mice), with all liver cells 
expressing tdTomato before Cre-mediated recombination; 
endogenous hepatocytes in mT/mG mice were then labeled 
following administration of adenoviral articles expressing 
Cre-recombinase under the control of the liver specific 
transthyretin (Ttr) promoter. Endogenous hepatocytes showed 
then positivity for EGFP membrane fluorescence and non-
parenchymal cells for tdTomato membrane fluorescence. MFs 
were generated following a protocol for experimental fibrosis 
based on chronic administration of carbon tetrachloride 
(CCl4) and, in order to overexpress the four TFs, a procedure 
requiring the administration of a p75NTRp-tagged 
recombinant adenoviral vector expressing the 4TFs from 
a polycistronic transgene cassette. In vivo targeting of MFs 
was obtained through portal vein administration of Ad.GFP-
S11-NGFp, a vector modified to couple adenoviral fiber 
knobs with a peptide fragment of NGF (NGFp) allowing 
specific binding to the p75 neurotrophin receptor (p75NTR) 
expressed on HSCs and MFs (22). Administration of Ad.GFP-
S11-NGFp carrying the 4TFs (Ad4TF) led to overexpression 
of the 4TFs in sorted MFs without any sign of morphological 
or liver function alteration. 
Authors, having established the model to identify iHeps 
reprogrammed from MFs, performed a number of experiments 
to evaluate iHep formation in vivo and to characterize them 
using different murine protocol of fibrosis induction. In 
first experiments using chronic CCl4 protocol (involving for 
mT/mG mice treatment with AAV-Ttr-Cre at time zero, 
CCl4 treatment twice a week from day 30 to 90, Ad4TF 
administration at day 97 and detection point at day 127) 
the following major data were obtained: (I) iHep were not 
detected when Ad4TF was administered to control animals 
(no chronic injury); (II) the percentage of iHep derived 
from MFs (i.e., positive for dTomato and hepatocyte 
markers) in chronically injured liver receiving Ad4TF, 
was estimated as 0.2–1.2% among the total hepatocyte 
population, corresponding to an estimated reprogramming 
efficiency of less than 4%; (III) iHep isolated from in vivo 
conditions and sorted as single-tdTomato positive cells (i.e., 
cells unequivocally converted from MFs) were functionally 
behaving as HLCs by secreting albumin and urea, taking up 
indocyanine green, storing glycogen and exhibiting activity 
of CYP3A and other Cytochrome-p450 isoforms; (IV) 
sorted dt-tomato-positive cells showed no chromosomal 
alterations and absence of expression of 4TFs, indicating 
stable reprogramming of MFs into iHep; (V) administration 
of Ad4TF resulted in a significant amelioration of CCl4-
induced liver fibrosis and injury as compared to animals 
treated with CCl4 but receiving the empty vector (as properly 
evaluated by assessing L-OH-proline hepatic levels, fibrosis 
score, Sirius red staining, immunohistochemical staining 
for desmin and p75NTR and aminotransferases levels). 
It is interesting to underline that similar results (with a 
percentage of iHep derived from MFs of 0.9–2.5%) were 
also obtained by employing a different lineage-tracing 
model like the mice expressing Cre under the transcriptional 
control of lecithin-retinol acetyltransferase (Lrat) promoter 
also containing mT/mG transgenes previously used to trace 
MFs deriving in vivo from activated HSCs (23). Moreover, 
the previously described major results, including the 
attenuation of liver fibrosis, were confirmed also in a model 
of cholestasis-induced liver fibrosis obtained in mice fed a 
3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. 
Of relevance, when the protocol was modified (i.e., 
by administering Ad4TF at day 60 during chronic CCl4 
administration), the procedure was still resulting in the 
in vivo generation of iHep and reduction of liver fibrosis 
during ongoing chronic liver injury. However, reduction of 
fibrosis and improvement of liver functions was not detected 
in mice treated with CCl4 for 12 weeks, mice that develop 
a murine histopathologic equivalent of cirrhosis, and then 
receiving Ad4TF. This lack of effect may depend on the 
fact that although the number of iHep reprogrammed was 
similar at 8 and 12 weeks, the number of MFs at 12 weeks 
was massively increased. Finally, overall in vivo and in vitro 
evidence provided in this study also outlines three additional 
relevant concepts: (I) the anti-fibrotic effect is due to 
the reduction of MFs rather than to suppression of MFs 
properties, fully in agreement with previous results (21-23); 
(II) following Ad4TF administration, iHep were detectable 
only in the liver (no evidence in other p75NTR-expressing 
tissues like brain, heart, lung and kidney), a result indicating 
that the procedure is then very selective for liver; (III) iHep 
generated in vivo were not the result of cell fusion, which is 
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an “old” but significant concern here correctly investigated 
and excluded. 
The outstanding study by Song et al. (17) is of extreme 
interest because it outlines a reliable novel therapeutic 
strategy designed to counteract and/or ameliorate 
fibrogenic progression of CLDs which are, at present, 
in relation to their increased worldwide incidence, the 
most relevant concern for hepatologists. Of course, since 
this can be considered as a pioneer study, there are still 
limitations as well as unanswered questions, some of these 
correctly acknowledged by authors (17). A first relevant 
obvious point relies on the fact that the efficiency of in 
vivo reprogramming of MFs is still relatively low, and 
then future studies should pursuit the goal to enhance 
the overall efficiency of iHep generation, possibly by 
improving targeted transduction (as Authors themselves 
suggest), in order to maximize positive effects. This is 
something that some of the Authors involved in the study 
are trying to finalize, as already show by data published 
in an accompanying paper in the same issue of Cell Stem 
Cell in which they used adeno-associated virus 6 (AAV6) 
vector expressing hepatic transcription factors (24). Another 
question is relying on the precise origin of in vivo iHep: 
although the models used in this study and literature data 
support a predominant origin from HSCs-derived MFs, 
one can not exclude that some iHep may originate from 
other cellular sources, including portal fibroblasts, smooth 
muscle cells around portal vein, bone marrow-derived 
mesenchymal stem cells or fibroblasts around central vein 
(18-23). Along these lines, and because data from this study 
indicate that iHep are detected only near to the portal vein 
or near central vein, it would be of interest to know what 
happens (i.e., in vivo procedures to reprogram MFs into 
iHep) in a murine model of the human non-alcoolic fatty 
liver disease (NAFLD, a major CLD worldwide), in which 
fibrosis starts with a peculiar perisinusoidal/pericellular 
pattern mainly involving activated HSCs. Similarly, 
since Authors state that they have detected limited, but 
significant, genetic memory of MFs, it would be nice to 
have information related to longer studies, in mice at this 
stage, to know whether the procedure could be considered 
overall safe. Finally, as recognized by Authors, one can 
not exclude that overexpression of TFs in endogenous 
hepatocytes may contribute to liver fibrosis amelioration, 
as already suggested for HN4A overexpression by a study 
performed on rat exposed chronically to CCl4 (25). 
However, all the limitations and unaswered questions 
seem really to disappear in front of an outstanding study 
that open a novel and very promising way to counteract 
in vivo fibrogenic progression of CLDs: it needs just to be 
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